Drug Sponsors

Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015 12:42 PM

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

More... »


Regado Biosciences, Tobira Therapeutics to merge

Wednesday, January 14, 2015 12:34 PM

Regado Biosciences, a development stage biotechnology company based in Basking Ridge, N.J., and Tobira Therapeutics, a clinical-stage biopharmaceutical company in South San Francisco, have agreed to merge. Privately held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases.

More... »


Qiagen acquires Enzymatics’ Enzyme Solutions Unit

Tuesday, January 13, 2015 10:30 AM

Qiagen, a Netherlands-based holding company, has acquired the Enzyme Solutions Unit of Enzymatics, a developer, manufacturer and OEM supplier of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare.

More... »

Biogen Idec to acquire Convergence Pharmaceuticals, expands neuropathic pain portfolio

Tuesday, January 13, 2015 09:30 AM

Biogen Idec has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to leverage Convergence’s experience in chronic pain research and clinical development to accelerate the growth of its pain portfolio.

More... »

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015 02:44 PM

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine's position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

More... »

Shire to acquire NPS Pharma for $5.2 billion

Monday, January 12, 2015 02:38 PM

Dublin, Ireland-based Shire and NPS Pharmaceuticals have entered into a merger agreement, under which Shire will acquire all outstanding shares of NPS Pharma for $46 per share in cash, for a total consideration of approximately $5.2 billion.

More... »

Evotec, Padlock Therapeutics extend collaboration

Monday, January 12, 2015 02:32 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, and Padlock Therapeutics, a private, Cambridge, Mass.-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases, have successfully completed an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.

More... »

Aveo announces executive transition, corporate restructuring

Thursday, January 8, 2015 12:59 PM

Aveo Oncology, based in Cambridge, Mass., has appointed Michael P. Bailey as the company’s president, CEO and director, effective immediately. Aveo also said it will eliminate the company’s internal research function, as well as certain corporate support positions, to align corporate resources with the company’s future strategic plans, focusing on advancement of its pipeline in the clinical setting.

More... »

Adaptive Biotechnologies acquires Sequenta

Thursday, January 8, 2015 12:55 PM

Adaptive Biotechnologies, a platform-based, diagnostic-driven company headquartered in Seattle, Wash., has acquired Sequenta, a California company focused on the development of clinical diagnostics using immunosequencing. The acquisition is expected to expedite and expand the use of novel immunosequencing products for researchers and clinicians to diagnose, treat and monitor patients with cancer, autoimmune disorders and infectious diseases.

More... »

Gilead Sciences acquires Phenex Pharmaceuticals’ NASH development program

Wednesday, January 7, 2015 12:42 PM

Gilead Sciences, a biopharmaceutical company headquartered in Foster City, Calif., and Phenex Pharmaceuticals, a privately held German biotechnology company, have signed a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs